BioCentury

7:00 AM GMT, Jul 7, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

The 2-day difference

Eisai Co. Ltd. and SuperGen Inc. aren’t expressing concern that Dacogen decitabine missed the primary endpoint of survival benefit in a European Phase III trial to treat myelodysplastic syndromes, as the partners maintain the trial used an outdated protocol. Although it’s unclear whether the negative outcome will affect a planned regulatory resubmission in Europe, the companies expect no changes in prescribing habits in the U.S., where the drug is already

Read the full 705 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.